Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Biosimilar Therapeutic Peptides Market Poised To Hit $6.11 Billion By 2030 With A 11.9% CAGR
The biosimilar therapeutic peptides market has experienced substantial growth in its size over recent years. It is projected to expand from $3.5 billion in 2025 to $3.9 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.5%. Historically, this expansion has been driven by factors such as the limited availability of biosimilar peptides, a reliance on innovative peptide therapies, the increasing prevalence of cancer and metabolic disorders, rising awareness of peptide-based treatments, and advancements in parenteral administration methods.
The biosimilar therapeutic peptides market is projected to experience substantial expansion over the upcoming years. This market is predicted to reach $6.11 billion by 2030, demonstrating an 11.9% compound annual growth rate (CAGR). Factors contributing to this expansion during the forecast period include the introduction of combination and long-acting peptides, increased generic peptide manufacturing, wider embrace of transdermal delivery systems, escalating investment in peptide research and development, and a rise in healthcare spending on peptide-based therapies. Key trends anticipated during this period encompass a growing need for biosimilar therapeutic peptides in cancer management, advancements in peptide-based treatments for metabolic and cardiovascular conditions, greater integration of long-acting and combination peptides, broadening of parenteral and transdermal administration pathways, and an emphasis on affordable generic peptides and their availability in developing markets.
Get A Free Sample Report With In-Depth Market Insights:
Biosimilar Therapeutic Peptides Market Growth Factors Behind Sustained Expansion
The biosimilar therapeutic peptide market is anticipated to be propelled by the rising prevalence of chronic diseases. These are enduring medical conditions necessitating continuous management and treatment, frequently spanning years or an entire lifespan. The growing incidence of chronic diseases fuels a heightened need for economical treatments, positioning biosimilar therapeutic peptides as an appealing choice owing to their affordability and capacity to enhance patient access and ensure healthcare system sustainability. Further market expansion is supported by regulatory endorsements and clinical data. As an illustration, in April 2025, data from the Centers for Disease Control and Prevention (CDC), a US-based federal agency, indicated that in 2023, around 194 million U.S. adults, or 76.4%, reported suffering from at least one chronic condition. The reported prevalence stood at 59.5% for young adults, 78.4% for midlife adults, and 93.0% for older adults. Consequently, the increasing prevalence of chronic diseases is projected to stimulate the expansion of the biosimilar therapeutic peptides market.
Biosimilar Therapeutic Peptides Market Segment Breakdown: Which Categories Lead On Revenue?
The biosimilar therapeutic peptides market covered in this report is segmented –
1) By Type: Innovative, Generic
2) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations
3) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders
Subsegments:
1) By Innovative: Long-Acting Peptides, Combination Peptides
2) By Generic: Monoclonal Antibodies, Hormones, Enzymes
Biosimilar Therapeutic Peptides Market Industry Trends Fueling Future Revenue Growth
Major companies in the biosimilar therapeutic peptide market are establishing a research platform focused on optimizing peptide synthesis, enhancing production efficiency, and ensuring consistent quality from discovery through commercialization. The Biodrug Design Accelerator is a platform developed to manage research processes for peptide drug discovery, an area many consider a promising frontier in new drug development. For instance, in May 2023, Fujitsu Limited, a US-based toy manufacturing and entertainment company, unveiled the Biodrug Design Accelerator platform to accelerate research into peptide drug discovery. The Biodrug Design Accelerator is set to support peptide drug discovery scientists in pharmaceutical companies by speeding up and improving the efficiency of peptide drug development, specifically via the design, make, test, analyze (DMTA) cycles. This ultimately enables the accelerated and informed design of peptide drug candidates, alongside efficient communication among scientists regarding synthesis and testing.
Biosimilar Therapeutic Peptides Market Leading Players And Competitive Positioning
Major companies operating in the biosimilar therapeutic peptides market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Novo Nordisk A/S, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd.
View The Full Biosimilar Therapeutic Peptides Market Report:
Biosimilar Therapeutic Peptides Market Largest Region By Revenue And Market Share
North America was the largest region in the biosimilar therapeutics peptides market in 2025. Middle East is expected to be the fastest growing region in the biosimilar therapeutic peptides market report during the forecast period. The regions covered in the biosimilar therapeutic peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
